No profile data available.
Amarin Corporation plc (AMRN) is a healthcare company in the metabolic process treatment drugs industry, based in Dublin, Ireland, with about 80 full-time employees.
It reported revenue of $213.65 million for fiscal year 2025, down 6.5% from fiscal year 2024, and net income of -$38.80 million. In Q1 2026 (the quarter ended March 31, 2026) revenue was $45.13 million, up 7.4% from a year before. US was its largest region in fiscal year 2025, with 84% of revenue. Its market capitalization was $252.26 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
Amarin Corporation plc, a pharmaceutical company, engages in the commercialization and development of therapeutics for the treatment of cardiovascular diseases in the United States, Europe, and internationally.
Amarin reported $213.65 million in revenue for fiscal year 2025, down 6.5% from $228.61 million in fiscal year 2024. In Q1 2026 revenue was $45.13 million.
US: 84% of revenue by region in fiscal year 2025, followed by Europe (10%).
$252.26 million as of October 9, 2026.
Listed companies of a similar size in the same industry (metabolic process treatment drugs) include Disc Medicine, Inc. (IRON), Maze Therapeutics, Inc. (MAZE), Zevra Therapeutics, Inc. (ZVRA), Camp4 Therapeutics Corp (CAMP).